Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Boettcher, Steffen  [Clear All Filters]
2019
Helbling PM, Piñeiro-Yáñez E, Gerosa R, Boettcher S, Al-Shahrour F, Manz MG, Nombela-Arrieta C. Global Transcriptomic Profiling of the Bone Marrow Stromal Microenvironment during Postnatal Development, Aging, and Inflammation. Cell Rep. 2019;29(10):3313-3330.e4.
2020
Boettcher S, C Wilk M, Singer J, Beier F, Burcklen E, Beisel C, Ferreira MSVentura, Gourri E, Gassner C, Frey BM, et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020.
C Wilk M, Manz MG, Boettcher S. Clonal hematopoiesis in hematopoietic stem cell transplantation. Curr Opin Hematol. 2020;Publish Ahead of Print.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou H-A, Eksioglu EAdriana, Sullivan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020.
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020;37(1):104-122.e12.
2022
Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+/- >clonal hematopoiesis via IL-1 signaling. Blood. 2022.
Sellar RS, Sperling AS, Słabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, et al. Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing normal hematopoietic stem cells. J Clin Invest. 2022.
2023
Carter BZ, Mak PYee, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13(1):57.
Carter BZ, Mak PYee Yee, Muftuoglu M, Tao W, Baozhen K, Jiang P, Bedoy AD, Ostermann LB, Nishida Y, Isqandarova S, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023.
Marion W, Koppe T, Chen C-C, Wang D, Frenis K, Fierstein S, Sensharma P, Aumais O, Peters M, Ruiz-Torres S, et al. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia. Leukemia. 2023.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, Dinardo CD, Takahashi K, Loghavi S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023;13(1):53.